Optimizing testing for neurotrophic tropomyosin receptor kinase (NTRK) gene fusions in appropriate adult and pediatric patients with solid tumors can identify those who may benefit from treatment with targeted TRK inhibitor therapy. Many pathologists and clinicians on the oncology care team may be unfamiliar with the clinical significance of NTRK gene fusions and with best practice diagnostic strategies for identifying TRK fusion solid tumors. In this interactive symposium, 2 pathologists and a medical oncologist will discuss the role and methods for NTRK fusion testing in select patients with solid tumors as well as clinical trial safety and efficacy data on available and emerging TRK inhibitors. The expert panel will also discuss strategies for improving communication between pathologists and medical oncologists to facilitate timely identification and treatment of patients with tumors harboring NTRK fusions.